3 Stocks At 52-Week Lows That Could Bounce Big
3 Stocks At 52-Week Lows That Could Bounce Big
One trading strategy an investor can profitably employ is to pick up an undervalued asset that has sold off due to factors that are extraneous or intrinsic to it. The strategy is premised on the belief that the asset can only go higher from this level.
投資者可以使用的一種有利可圖的交易策略是買入被低估的資產，這些資產由於與其無關或內在的因素而被拋售。這一戰略的前提是相信資產只能在這個水平上走得更高。
52-week Low As A Trading Signal: How do you zero in an undervalued stock? One approach would be to look around for a stock, or for that matter any asset, which is trading at or near its 52-week low. A 52-week low is the lowest level at which the stock has traded for the year.
作為交易信號的52周低點：你如何將被低估的股票歸零？一種方法是四處尋找一隻股票，或者就這一點而言，任何資產的交易價格都在或接近52周低點。52周低點是該股今年以來的最低交易水平。
Not all stocks that hit the lows for the year could turn out to be a profitable trade. Some of these stocks may have deteriorating fundamentals, and this could precipitate the weakness further. An astute investor, therefore, should also weigh in several other factors such as competitive positioning, market opportunity, regulatory environment, financial soundness, etc.
並不是所有觸及年內低點的股票都可能成為有利可圖的交易。其中一些股票的基本面可能正在惡化，這可能會進一步加劇疲軟。因此，一個精明的投資者還應該權衡其他幾個因素，如競爭定位、市場機會、監管環境、財務穩健等。
This approach is similar to "value buying" propounded by the likes of Warren Buffett. A value investor will focus on buying undervalued shares of companies, which have fairly robust fundamentals.
這種方法類似於沃倫·巴菲特(Warren Buffett)等人提出的“價值購買”。價值投資者將專注於購買被低估的公司股票，這些公司的基本面相當強勁。
Here are three stocks trading at or near their 52-week lows and promise strong upside potential.
以下是三隻處於或接近52周低點的股票，有望實現強勁的上行潛力。
ADC Therapeutics SA (NYSE:ADCT)
ADC治療公司(紐約證券交易所：ADCT)
This Swiss-based biopharma focuses on developing antibody-drug conjugates for treating patients with hematological malignancies and solid tumors.
這家總部設在瑞士的生物製藥公司專注於開發抗體-藥物結合物，用於治療血液惡性腫瘤和實體腫瘤患者。
The company's shares hit a 52-week low of $21.51 in early March and have come off the level since then.
該公司股價在3月初觸及52周低點21.51美元，此後已回落。
ADC reported in mid-March a wider loss for its fourth quarter and fiscal year 2020, amid ballooning operating expenses. The company had a cash balance of $439.2 million as of Dec. 31.
ADC在3月中旬報告稱，由於運營費用不斷膨脹，其第四季度和2020財年出現了更大範圍的虧損。截至12月31日，該公司的現金餘額為4.392億美元。
Its lead candidate is loncastuximab tesirine, called Lonca, which has demonstrated significant single-agent clinical activity across a broad population of patients with relapsed or refractory diffuse large B-cell, mantle cell, and follicular lymphomas.
它的主要候選藥物是LonCastuximab tesiine，稱為LONCA，已在廣泛的復發或難治性瀰漫性大B細胞、套細胞和濾泡性淋巴瘤患者中顯示出顯著的單藥臨牀活性。
ADC has several upcoming catalysts and if these play out positively, its stock could be in for a big reversal. The company's biologic license application for Lonca in relapsed or refractory DLBCL has a PDUFA action date of May 21. H.C. Wainwright ascribes a 75-95% probability of Lonca being approved.
ADC即將推出幾個催化劑，如果這些催化劑發揮積極作用，其股價可能會出現大幅逆轉。該公司對Lonca治療復發或難治性DLBCL的生物許可證申請的PDUFA行動日期為5月21日。H.C.温賴特認為隆卡獲得批准的可能性為75%-95%。
The average price target of analysts covering the biopharma's stock is $48.
研究這家生物製藥公司股票的分析師的平均目標價為48美元。
Related Link: Why It's A Great Time To Be A Value Investor
相關鏈接：為什麼現在是價值投資者的大好時機
BigCommerce Holdings, Inc. (NASDAQ:BIGC)
BigCommerce Holdings，Inc.(納斯達克：BIGC)
BigCommerce is an open SaaS e-commerce platform for brands. The company offered its shares to the public in the middle of the COVID-19 pandemic. After a whopping listing gain of about 200%, the stock ran up to a high of $162.50 in the first month of listing.
BigCommerce是一個面向品牌的開放SaaS電商平臺。該公司在新冠肺炎大流行期間向公眾發行股票。在經歷了約200%的巨大上市漲幅後，該股在上市的第一個月就漲到了162.50美元的高點。
On Tuesday, the stock hit a 52-week low of $50.59.
週二，該股觸及52周低點50.59美元。
Piper Sandler analyst Brent Bracelin said in a note in early March that he sees multiple upside levers to growth estimates of 25%+ over the next one to three years. Incremental growth could come from new $1 billion, plus, gross merchandise value merchants, international expansion, accelerating partner-driven new merchants, new investments and further expansion into B2B.
派珀·桑德勒(Piper Sandler)分析師布倫特·布拉克林(Brent Bracelin)在3月初的一份報告中表示，他認為未來一到三年25%以上的增長預期存在多個上行槓桿。增量增長可能來自新的10億美元，加上商品總價值商家、國際擴張、加速合作伙伴驅動的新商家、新投資和進一步向B2B擴張。
"As a cloud commerce pure-play with what we see as $1B+ revenue potential, we would be aggressive buyers of BIGC on the recent pull-back and view it as a core small-cap growth holding," Bracelin said in the note.
Bracelin在報告中表示：“作為一家純粹的雲商務公司，我們認為BIGC有超過10億美元的營收潛力，我們將在最近的回調中積極買入BIGC，並將其視為核心的小盤股增長持股。”
Ganfeng Lithium Co., Ltd. (OTC:GNENF)
贛鋒鋰業股份有限公司(場外交易：GNENF)
Ganfeng Lithium is a China-based supplier of lithium, which is used in the batteries of EVs. It counts Tesla, Inc. (NASDAQ:TSLA) and Bayerische Motoren Werke Aktiengesellschaft (OTC:BMWYY) among its customers.
Rising demand from the booming EV industry led to a strong financial performance by the company in fiscal year 2020. The industry is gradually shifting from a balanced supply and demand to a tight supply situation, the company said. This is validated by Romeo Power, Inc.'s (NASDAQ:RMO) warning that it won't be able to meet battery pack delivery commitments to customers in 2021 due to a shortage of batteries.
蓬勃發展的電動汽車行業不斷增長的需求導致該公司在2020財年實現了強勁的財務表現。該公司表示，該行業正逐漸從供需平衡轉向供應緊張局面。這一點通過以下方式進行驗證羅密歐電力公司(Romeo Power，Inc.)(納斯達克：RMO)警告稱，由於電池短缺，該公司將無法在2021年實現向客户交付電池組的承諾。
Ganfeng Lithium stock, which is traded over the counter, hit a 52-week low of $11 on March 8 and is currently trading around $12.50.
在場外交易的贛鋒鋰業股票在3月8日觸及52周低點11美元，目前交易價格在12.50美元左右。
譯文內容由第三人軟體翻譯。